Companies › Prime Gene Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PG-011 Gel | – | Phase 3 | Atopic Dermatitis | – |
| PG-033 | – | Phase 1 | Lichen Simplex Chronicus | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06587685 | PG-011 Gel | Phase 3 | Atopic Dermatitis | Immunology | Nov 2024 |
| NCT07013097 | PG-033 | Phase 1 | Lichen Simplex Chronicus | Immunology | Dec 2026 |
No annotated target.
–
Hangzhou Highlightll Pharmaceutical Paradigm Biopharmaceuticals Sagimet Biosciences BioCryst Pharmaceuticals Arthrosi Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.